drugset / Trial / NCT05061277
Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Recifercept in Healthy Chinese Participants
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the pharmacokinetic (PK), safety, tolerability and immunogenicity of a single subcutaneous (SC) dose of the lyophilized formulation of recifercept in healthy Chinese participants.
Timeline
- Start
- 2023-10-25
- Primary completion
- 2023-12-12
- Completion
- 2024-06-16
Outcome
Outcome not reported
Stopped (Enrollment): “Pfizer has decided to cancel study C4181006 due to strategic considerations. This decision is not due to any specific reasons or requests from any regulatory authorities. No participants have been enrolled in this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Recifercept | Protein / enzyme biologic | 300 mg | Subcutaneous |
Indications
No indication recorded.